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Methods A three-phase double-blind, placebo- and diet-
controlled randomized intervention study was conducted. 
Phase 1 was an 8-week-periodized resistance-training 
program; Phase 2 was a 2-week overreaching cycle; and 
Phase 3 was a 2-week taper. Muscle mass, strength, and 
power were examined at weeks 0, 4, 8, and 12 to assess 
the chronic effects of HMB-FA; and assessment of these, as 
well as cortisol, testosterone, and creatine kinase (cK) was 
performed at weeks 9 and 10 of the overreaching cycle.
Results HMB-FA resulted in increased total strength 
(bench press, squat, and deadlift combined) over the 
12-week training (77.1 ± 18.4 vs. 25.3 ± 22.0 kg, 
p < 0.001); a greater increase in vertical jump power 
(991 ± 168 vs. 630 ± 167 W, p < 0.001); and increased 
lean body mass gain (7.4 ± 4.2 vs. 2.1 ± 6.1 kg, 
p < 0.001) in HMB-FA- and placebo-supplemented groups, 
Abstract 
Introduction Studies utilizing beta-hydroxy-beta-meth-
ylbutyrate (HMB) supplementation in trained populations 
are limited. no long-term studies utilizing HMB free acid 
(HMB-FA) have been conducted. therefore, we investi-
gated the effects of 12 weeks of HMB-FA supplementa-
tion on skeletal muscle hypertrophy, body composition, 
strength, and power in trained individuals. We also deter-
mined the effects of HMB-FA on muscle damage and per-
formance during an overreaching cycle.
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respectively. During the overreaching cycle, HMB-FA 
attenuated increases in cK (−6 ± 91 vs. 277 ± 229 IU/l, 
p < 0.001) and cortisol (−0.2 ± 2.9 vs. 4.5 ± 1.7 μg/dl, 
p < 0.003) in the HMB-FA- and placebo-supplemented 
groups, respectively.
Conclusions these results suggest that HMB-FA 
enhances hypertrophy, strength, and power following 
chronic resistance training, and prevents decrements in per-
formance following the overreaching.
Keywords leucine metabolite · resistance training · 
Overreaching · recovery · Sports supplements
Abbreviations
HMB  beta-Hydroxy-beta-methylbutyrate
HMB-ca  calcium HMB
cK  creatine kinase
HMB-FA  HMB free acid
lBM  lean body mass
1-rM  One-repetition maximum
Vl  Vastus lateralis
VI  Vastus intermedius
Introduction
nearly two decades ago, nissen et al. (1996) became the 
first to demonstrate that supplementation of the leucine 
metabolite, beta-hydroxy-beta-methylbutyrate (HMB), 
combined with resistance training improved protein bal-
ance and augmented gains in lean body mass (lBM) and 
strength. Since that time the most robust effects of HMB 
have been demonstrated in untrained individuals, who 
have experienced increased lBM and strength in as little 
as 3 weeks following supplementation (Jowko et al. 2001; 
nissen et al. 1996). Presently, HMB is thought to operate 
via enhanced recovery of damaged skeletal muscle tissue 
(Wilson et al. 2008). thus, these findings are not surpris-
ing as research clearly indicates that the initial weeks of 
training result in the highest magnitude of damage in an 
untrained population (clarkson and Hubal 2002; McHugh 
et al. 1999). However, novices become resistant to damage 
during non-periodized training programs and their adapta-
tions diminish (turner 2011). therefore, it is likely that the 
most important independent variables in any study examin-
ing HMB supplementation in athletes may be the intensity 
and variability of the training protocol.
to date, the overwhelming majority of studies in 
trained individuals have been non-periodized and unsu-
pervised (Kreider et al. 1999; thomson et al. 2009). the 
first study conducted in trained individuals supplement-
ing with HMB found no differences between conditions. 
However, the investigators of this study did not monitor 
the training of their participants and instructed them to 
maintain the same training routine that they had prior to 
the start of the study (Kreider et al. 1999). currently, only 
one study has included a high-intensity, monitored, resist-
ance-training protocol in highly trained athletes (nissen 
et al. 1996). However, this study lacked a high degree of 
variation, and was only 7 weeks in duration. thus, there 
is a clear need for more long-term studies in resistance-
trained populations, subjected to periodized, high-intensity 
resistance-training protocols. Moreover, it is essential to 
utilize direct measures of skeletal muscle hypertrophy and 
to monitor each resistance-training session to limit poten-
tial confounding variables that may have an effect on a 
true outcome.
recently, HMB in a free acid form (HMB-FA) has 
been developed with improved bioavailability (Fuller 
et al. 2011). Initial studies have shown that this form of 
HMB supplementation results in approximately double the 
plasma levels of HMB in about one-quarter the time after 
administration when compared with the presently avail-
able form calcium HMB (HMB-ca). In addition, this study 
showed that the HMB-FA had a 25 % greater clearance by 
the body, indicating improved utilization. Further, we have 
found that HMB-FA given 30 min prior to an acute bout 
of high-volume resistance training was able to attenuate 
indices of muscle damage and improve perceived recovery 
in resistance-trained athletes (Wilson et al. 2013b). More 
recently, acute ingestion of 3.4 g of HMB-FA has been 
demonstrated to increase skeletal muscle protein synthe-
sis and decrease protein breakdown by +70 and −56 %, 
respectively (Wilkinson et al. 2013). to date, however, the 
majority of studies have been conducted using HMB-ca 
(Wilson et al. 2008; 2013a).
therefore, the primary purpose of this study was to 
investigate the effects of 12 weeks of HMB-FA supplemen-
tation in resistance-trained individuals during a monitored 
periodized resistance-training program on skeletal muscle 
hypertrophy, body composition, strength, and power rela-
tive to a placebo-matched control group. the secondary 
purpose of our investigation was to determine if HMB-FA 
was able to prevent the typical decay seen in performance 
following an overreaching cycle performed in the 9th and 
10th weeks of the study.
Methods
Overview
the current study was a randomized, double-blind, pla-
cebo- and diet-controlled experiment consisting of a 
12-week-periodized resistance-training program. the 
1219Eur J Appl Physiol (2014) 114:1217–1227 
1 3
training protocol was divided into three phases and con-
sisted of a non-linear-periodized resistance-training pro-
gram for the first 8 weeks, followed by a 2-week overreach-
ing cycle, and finally a 2-week taper of the training volume 
(tables S1–S3). Muscle mass, body composition, strength, 
power, resting plasma testosterone, cortisol, and creatine 
kinase (cK) levels were examined collectively at the end of 
weeks 0, 4, 8, and 12 to assess the chronic effects of HMB; 
these measures were also assessed at the end of weeks 9 
and 10, corresponding to the mid- and endpoints of the 
phase 2 overreaching cycle. the study was approved by the 
University of tampa Institutional review Board and regis-
tered with clinicaltrials.gov (nct01508338).
Participants
twenty-four resistance-trained males were tested and 
included in the study. Subjects were organized into quar-
tile blocks based on their lBM and strength. Following 
this, each quartile was randomized to one of the treatment 
groups using computer-generated random numbers. After 
treatment assignment, the groups were assessed to con-
firm there were no differences between groups. Of those 
randomized to the treatments, three subjects dropped 
from the placebo group, two because of injury and one 
because of the time commitment, while one dropped from 
the HMB-FA group due to injury. All drop outs occurred 
during the first 4 weeks of the study. the remaining 20 
subjects (21.6 ± 0.5 years of age) consisting of nine pla-
cebo (87.1 ± 4.8 kg; 180.9 cm) and 11 supplemented 
(83.1 ± 2.8 kg; 179.0 ± 2.1) males with an average squat, 
bench press, and deadlift of 1.7 ± 0.04, 1.3 ± 0.04, and 
2.0 ± 0.05 times their bodyweight, respectively, com-
pleted the study. there were no significant differences for 
age, body weight, height, or BMI between the treatment 
groups at the start of the study. Participants were excluded 
if they were currently taking anti-inflammatory agents as 
well as any other performance-enhancing supplement, 
or if they smoked. the participants must not have taken 
any nutritional supplements for at least 3 months prior 
to the start of data collection. Each participant signed an 
informed consent approved by the University of tampa 
Institutional review Board before participating in the 
study in the Department of Health Sciences and Human 
Performance at the University of tampa, tampa, Fl, 
USA.
Strength, power, body composition, and skeletal muscle 
hypertrophy testing
Strength was assessed via a one-repetition maximum 
(1-rM) testing of the back squat, bench press, and dead-
lift. the intraclass correlation coefficient (Icc) for the 
test–retest of strength in the squat, bench press, and dead-
lift ranged from r = 0.956 to 0.982. Body composition 
[lBM, fat mass (FM), and total mass] was determined on 
a lunar Prodigy dual X-ray absorptiometry (DXA) appa-
ratus (software version, encOrE 2008, Madison, WI, 
USA). tests for the DXA were performed at the same 
time of day in a fasted state and the Icc was r = 0.981. 
Skeletal muscle hypertrophy was assessed via changes in 
ultrasonography (gE logiq e 2008, Wauwatosa, WI, USA) 
determined combined muscle thickness of the vastus lat-
eralis (Vl) and vastus intermedius (VI) muscles. the Icc 
for the test–retest of muscle thickness measurements was 
r = 0.975.
Peak power (PP) was assessed during maximal cycling 
(modified Wingate test) and jumping movements. Dur-
ing the cycling test, the volunteer was instructed to cycle 
against a predetermined resistance (7.5 % of body weight) 
as fast as possible for 10 s (Smith et al. 2001) on a cycle 
ergometer (Monark model 894e, Vansbro, Sweden). Win-
gate PP was recorded using Monark anaerobic test software 
(Version 1.0, Monark, Vansbro, Sweden). From completion 
of Wingate tests performed over several days, the Icc for 
Wingate PP was 0.966.
Measurements of PP for the vertical jump were 
also taken on a multicomponent AMtI force platform 
(Advanced Mechanical technology, Watertown, MA USA) 
which interfaced with a personal computer at a sampling 
rate of 1,000 Hz (lowery et al. 2012). Data acquisition 
software (labVIEW, version 7.1; national Instruments 
corporation, Austin, tX, USA) was used to calculate verti-
cal jump PP. the Icc for VJ PP was 0.971.
Supplementation, diet control, and exercise protocol
Prior to the study, participants were randomly assigned to 
receive either 3 g per day of HMB-FA or a placebo divided 
equally into three servings. Each serving was formulated 
with 1 g of HMB-FA. the first serving was given 30 min 
prior to exercise and the remaining two servings given with 
the mid-day and evening meals. On the non-training days, 
participants were instructed to consume one serving with 
each of three separate meals throughout the day. Blinding 
occurred via an outside researcher who sent an isocaloric 
supplement and placebo in identical looking and flavored 
packets containing either 3 g per day of HMB-FA (com-
bined with food-grade orange flavors and sweeteners) or 
a placebo (corn syrup combined with food-grade orange 
flavors and sweeteners) divided equally into three serv-
ings daily. this researcher was not involved in direct data 
collection, or statistical analysis, and did not meet any of 
the subjects. For this reason, neither the researchers con-
ducting the study, nor the subjects knew which participant 
was assigned to which group. Moreover, the code was not 
1220 Eur J Appl Physiol (2014) 114:1217–1227
1 3
broken until after all of the data were entered into a com-
puter spreadsheet, and sent to an outside researcher who 
was also blinded to the treatment groups. the supplementa-
tion was continued daily throughout the training and test-
ing protocols. two weeks prior to and throughout the study, 
participants were placed on a diet consisting of 25 % pro-
tein, 50 % carbohydrates, and 25 % fat by a registered die-
tician (M.S., rD, lD) who specialized in sports nutrition. 
the participants met as a group with the dietitian, and they 
were given individual meal plans at the beginning of the 
study. Diet counseling was continued throughout the dura-
tion of the study. Assessment of 3-day food records taken 
at the beginning, mid, and last week of the study revealed 
that diets consisted of 22 % protein, 45 % carbohydrates, 
and 33 % fat, with no differences between groups. com-
pliance of supplementation was assessed by having the 
participants hand their empty packets to a researcher at the 
beginning of each training day. compliance was over 98 % 
for supplementation.
the purity of HMB-FA was determined by the manu-
facturer (tSI, Missoula, Mt, USA) using high-pressure 
liquid chromatography to be 99.7 %. the primary impuri-
ties were acetate and water. Metabolic technologies Inc. 
(MtI, Ames, IA, USA) independently assayed the HMB-
FA for purity and confirmed these results. In addition, MtI 
assayed HMB-FA for dehydroepiandrosterone (DHEA) 
a contaminant which has been found in nutritional sup-
plements using gas chromatography–mass spectrometry 
(thuyne and Delbeke 2005). DHEA was not detected in 
the HMB-FA (<1 ng/g). In addition, a sample was sent to 
an independent laboratory (MVtl, new Ulm, Mn, USA) 
for microbial and heavy metals testing. HMB-FA tested 
negative for E. coli, Listeria, and Salmonella. copper, zinc, 
calcium, mercury, cadmium, and lead were less than the 
instrument’s detection limits and arsenic was detected at 37 
PPB.
Exercise protocols
the training was divided into three phases, with Phase 1 
(table S1) consisting of a daily undulating periodized 
resistance-training program 3 days per week during weeks 
1 through 8. this protocol was modified from Kraemer 
et al. (2009). Phase 2 (table S2) consisted of a 2-week 
overreaching cycle during weeks 9 and 10 wherein par-
ticipants resistance trained 5 days per week and also per-
formed an additional day of Wingate and power testing. 
Finally, phase 3 (table S3) consisted of a tapered training 
volume for weeks 11 and 12. All training sessions were 
monitored and controlled by the researchers, and if a ses-
sion was missed at a specific time of day it was made up 
within 24 h. Using this criterion, compliance was 100 % for 
all subjects who completed the study.
resting blood draws
All blood draws throughout the study were obtained via 
venipuncture after a 12 h fast by a trained phlebotomist. 
All blood draws were scheduled at the same time of day 
to negate confounding influences of diurnal hormonal 
variations. Whole blood was collected and transferred into 
appropriate tubes for obtaining serum and plasma and cen-
trifuged at 1,500 g for 15 min at 4 °c. resulting serum and 
plasma were then aliquoted and stored at −80 °c until sub-
sequent analyses. A portion of the blood samples taken at 
weeks 0, 4, 8, and 12 were used for measurements (Any 
lab test now®, tampa, Fl, USA) of glucose, blood urea 
nitrogen, creatinine, egFr, na+, K+, cl−, cO2, ca2+, pro-
tein, albumin, globulin, albumin:globulin ratio, total biliru-
bin, alkaline phosphatase, aspartate aminotransferase, and 
alanine aminotransferase. A complete blood count was also 
performed on each blood sample. In addition, a urinalysis 
(urine specific gravity, pH, and Urobilinogen) was con-
ducted on a sample of urine. the samples were submitted 
to an outside laboratory for analysis (Any lab test now®, 
tampa, Fl, USA) at weeks 0, 4, 8, and 12.
Biochemical analysis
Samples were thawed one time and analyzed in duplicate 
for each analyte. Serum total and free testosterone, cortisol, 
and c-reactive protein (crP) were assayed via ElISA kits 
(Diagnostic Systems laboratories, Webster, tX, USA). All 
hormones were measured in the same assay on the same 
day to avoid interassay variation. All samples were ana-
lyzed in duplicate. the intra-assay variance was calculated 
by coefficient of variation [(SD/mean) × 100]. Intra-assay 
variance was determined to be <3 % for all analytes. Serum 
cK was measured at 340 nm using colorimetric procedures 
(Diagnostics chemicals, Oxford, ct, USA). As a measure 
of muscle protein degradation, the ratio of urinary 3-meth-
ylhistidine to creatinine (3MH:cr) was calculated. the par-
ticipants were instructed to consume a meat-free diet for 
72 h prior to each measurement period at weeks 8, 9, and 
10. Urine was collected for 24 h, uniformly mixed, sam-
pled, and then stored at −80 °c until subsequent analyses. 
the 3MH was measured using a previously described gc/
MS method (rathmacher et al. 1992). Urinary creatinine 
(cr) was measured using a colorimetric Jaffe’s reaction 
(cayman chemical, Ann Arbor, MI, USA). the 3MH:cr 
ratio over the 24-h period was then calculated.
Perceived recovery status scale
Perceived recovery status (PrS) scale was measured at 
weeks 0, 4, 8, 9, 10, and 12 to assess subjective recovery 
during the training phases. the PrS scale consists of values 
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between 0 and 10, with 0–2 being very poorly recovered 
with anticipated declines in performance, 4–6 being low 
to moderately recovered with expected similar perfor-
mance, and 8–10 representing high perceived recovery with 
expected increases in performance. the PrS scale has been 
demonstrated as a valid cognitive indicator of performance 
and fatigue (laurent et al. 2011; Sikorski et al. 2013).
Statistics
A one-way AnOVA model was used to analyze the baseline 
characteristic data using the Proc glM procedure in SAS 
(SAS Institute, cary, nc, USA). the primary outcome meas-
ure of this double-blind, placebo- and diet-controlled rand-
omized intervention study was muscular strength and power. 
the secondary outcome measure was muscle hypertrophy. 
the main effect of treatment (trt) was included in the model. 
changes over the 12-week study were analyzed by repeated 
measures AnOVA using the Proc Mixed procedure in SAS 
with the initial week of the period, week 0, used as a covari-
ate and the main effects were time, trt, and trt × time. In 
addition, the overreaching phase of the study was further 
assessed using a repeated measures AnOVA with Proc Mixed 
procedure in SAS with the week 8 time point used as a covar-
iate and the main effects were time, trt, and trt × time. 
least squares means procedure was then used to compare 
treatment means at each time point. the n size was based on 
a power analysis of lBM differences found by Kraemer et al. 
(2009). Statistical significance was determined at p ≤ 0.05. 
the results are presented as mean ± standard deviations.
Results
Muscle strength and power
HMB-FA supplementation resulted in a significant increase 
in strength gain compared with placebo supplementation for 
squat, bench press, deadlift, and total strength (table 1). After 
12 weeks of training, HMB-FA supplementation resulted in 
strength increases of 25 % for the squat, 12 % for the bench 
press, 16 % for the deadlift, and 18 % for total strength, 
which were significantly greater than the increases of 5 % 
for the squat, 3 % for the bench press, 9 % for the deadlift, 
and 6 % for total strength in the placebo group. total strength 
increases over the 12-week study were 25.3 ± 22.0 kg in the 
Table 1  Effect of beta-hydroxy-beta-methylbutyrate free acid (HMB-FA) supplementation on muscle strength and power in participants per-
forming a 12-week resistance-training regimen
Adjusted least square mean ± SD for n = 11 HMB (3 g HMB-FA/d in three 1 g doses) and n = 9 placebo-supplemented participants
a
 Probability of treatment by time difference between the placebo and the HMB-FA treatments over the 12-week study. the mixed model 
AnOVA in SAS® was used with the main effects of treatment, time and treatment by time, with the value for week 0 used as a covariate
b
 total strength as the sum of the 1-rM in bench press, squat, and deadlift
#
 Significantly different than corresponding placebo, t test (p < 0.05)
Week of study p valuea
0 4 8 12
total strengthb (kg)
 Placebo 426.7 ± 14.5 444.6 ± 14.5 457.8 ± 14.5 452.0 ± 14.5
 HMB-FA 426.7 ± 14.5 458.7 ± 14.5 477.6 ± 14.5 503.8 ± 14.5 0.0001
Squat (kg)
 Placebo 143.8 ± 5.2 150.4 ± 5.2 155.4 ± 5.2 151.1 ± 5.2
 HMB-FA 143.7 ± 5.2 154.9 ± 5.2 162.4 ± 5.2# 179.9 ± 5.2# 0.0001
Bench press (kg)
 Placebo 112.9 ± 6.6 116.4 ± 6.6 118.5 ± 6.6 116.7 ± 6.6
 HMB-FA 112.4 ± 6.6 120.8 ± 6.6 123.7 ± 6.6 125.2 ± 6.6# 0.02
Deadlift (kg)
 Placebo 170.4 ± 9.2 178.2 ± 9.2 184.3 ± 9.2 184.5 ± 9.2
 HMB-FA 170.3 ± 9.2 182.7 ± 9.2 191.2 ± 9.2 198.4 ± 9.2# 0.009
Wingate peak power (W)
 Placebo 879.1 ± 38.3 927.0 ± 38.3 987.2 ± 38.3 982.5 ± 38.3
 HMB-FA 879.7 ± 38.3 936.0 ± 38.3 980.7 ± 38.3 1,038.6 ± 38.3# 0.01
Vertical jump power (W)
 Placebo 5,224 ± 73 5,636 ± 73 5,839 ± 73 5,854 ± 73
 HMB-FA 5,219 ± 73 5,835 ± 73# 6,039 ± 73# 6,211 ± 73# 0.001
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placebo-supplemented participants, and 77.1 ± 18.4 kg in 
the HMB-FA-supplemented participants. Mean total strength 
also demonstrated that the HMB-FA supplementation group 
was significantly greater at 4, 8, and 12 weeks during the 
periodized resistance-training phases compared to the mean 
total strength in the placebo-supplemented group.
Wingate PP increased more in the HMB-FA-supple-
mented participants than in the placebo-supplemented par-
ticipants over the 12-week study. HMB-FA-supplemented 
participants increased Wingate PP by 18 % compared with 
a 12 % increase in placebo-supplemented participants 
(table 1). the 12-week mean Wingate PP was also sig-
nificantly greater in the HMB-FA group compared to the 
placebo group. A similar difference in vertical jump power 
was seen between the HMB-FA group and placebo group). 
Vertical jump power in the HMB-FA group increased 19 % 
after 12 weeks compared to the placebo group increase 
of 12 %. the mean vertical jump power was significantly 
improved with HMB-FA supplementation in comparison to 
the placebo at weeks 4, 8, and 12.
the increase in training volume, and decrease in recov-
ery during overreaching phase, significantly decreased 
strength in the placebo group (table 2). these decrements 
consisted of average decrements of −5.6 % for the squat, 
−4.8 % for the bench press, and −4.5 % for total strength 
compared to the HMB-FA group, whom had average decre-
ments in strength of −0.6 % for the squat, −1.0 % for the 
bench press, and −0.4 % for total strength. While not signif-
icantly different over both weeks of the overreaching cycle, 
the decrease in deadlift strength in the placebo group after 
the first week of overreach was significantly greater than the 
decrease in the HMB-FA group after 1 week of the over-
reaching phase, −5.6 vs. −1.5 %, respectively. the total 
strength decrease during the 2-week overreaching phase 
was −20.2 ± 15.2 kg in the placebo group, while the HMB-
FA group decrement was −2.0 ± 18.6 kg, which was sig-
nificantly different between groups. In addition, mean total 
strength was significantly greater in the HMB-FA group at 
weeks 9 and 10 compared with placebo group (table 2).
Body composition and muscle measurement
Supplementation with HMB-FA resulted in a significant 
increase in body mass and lBM compared with placebo 
Table 2  Effect of beta-hydroxy-beta-methylbutyrate free acid (HMB-FA) supplementation on muscle strength and power during the overreach-
ing phase, weeks 8, 9, and 10, of a 12-week resistance-training regimen
Adjusted least square mean ± SD for n = 11 HMB (3 g HMB-FA/d in three 1 g doses) and n = 9 placebo-supplemented participants
a
 Probability of treatment by time difference between the placebo and the HMB-FA treatments over weeks 8, 9, and 10, the overreaching por-
tion of the 12-week study. the mixed model in SAS was used with the main effects of treatment, week and treatment by week, with the value for 
week 8 as a covariate
b
 total strength as the sum of the 1-rM in bench press, squat, and deadlift
#
 Significantly different than corresponding placebo, t test (p < 0.05)
Week of study p valuea
8 9 10
total strengthb (kg)
 Placebo 467.8 ± 11.9 443.6 ± 11.9 447.6 ± 11.9
 HMB-FA 469.4 ± 11.9 464.5 ± 11.9# 467.3 ± 11.9# 0.01
Squat (kg)
 Placebo 159.2 ± 4.8 152.6 ± 4.8 150.6 ± 4.8
 HMB-FA 159.3 ± 4.8 158.3 ± 4.8# 162.6 ± 4.8# 0.0001
Bench press (kg)
 Placebo 121.4 ± 4.7 113.5 ± 4.7 115.6 ± 4.7
 HMB-FA 121.4 ± 4.7 120.3 ± 4.7# 120.1 ± 4.7# 0.05
Deadlift (kg)
 Placebo 187.2 ± 6.9 177.3 ± 6.9 181.4 ± 6.9
 HMB-FA 188.8 ± 6.9 185.9 ± 6.9 184.7 ± 6.9 0.26
Wingate peak power (W)
 Placebo 983.9 ± 38.8 917.5 ± 38.8 939.5 ± 38.8
 HMB-FA 977.6 ± 38.8 965.4 ± 38.8# 972.7 ± 38.8# 0.04
Vertical jump power (W)
 Placebo 5,949 ± 57.5 5,723 ± 57.5 5,656 ± 57.5
 HMB-FA 5,949 ± 57.5 5,867 ± 57.5# 5,870 ± 57.5# 0.0001
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supplementation (table 3) during the 12-week exercise 
training period. the HMB-FA group also experienced a 
significant decrease in body fat, −5.4 ± 1.6 kg, compared 
with the placebo group, −1.7 ± 2.7 kg (table 3). Supple-
mentation with HMB-FA resulted in significantly greater 
quadriceps thickness compared to the placebo group over 
the 12-week training period.
Muscle damage, hormonal status, and performance 
recovery scale
Supplementation with HMB-FA diminished the rise 
in cK following training over the 12-week study com-
pared with the placebo-supplemented group (table 4). At 
4 weeks, cK levels were significantly less in the HMB-
FA group compared with the placebo group. While no 
significant treatment effects were observed for serum 
crP levels, serum cortisol levels decreased in the HMB-
FA group in comparison to an increase in the placebo 
group. there were no significant changes in either free or 
total testosterone during the study (data not shown). Sup-
plementation with HMB-FA improved the participants’ 
perceived recovery from the previous bouts of exercise 
compared with the placebo-supplemented group which 
decreased in perceived recovery (table 4). In addition, 
the mean PrS in the HMB-FA group was significantly 
higher than the mean PrS indicated by the placebo group 
at weeks 8 and 12.
the increase in training volume with the overreaching 
phase resulted in a significant (108 %) increase in serum 
cK in the placebo group over the 2 weeks of training dur-
ing weeks 9 and 10, while cK in the HMB-FA did not 
change. Serum cK levels in the HMB-FA group were 
significantly lower after each week, 9 and 10, of the over-
reaching phase. A similar decrease was observed for serum 
lDH in the HMB-FA group (Data not shown). Measure-
ment of the urinary 3MH:cr ratio, an indicator of the rate 
of muscle protein degradation, during the 2-week over-
reaching period showed no significant effect of HMB-FA 
supplementation (table 5).
Safety studies
there were no differences in blood chemistry and hema-
tology between the placebo- and HMB-FA-supplemented 
groups. In addition, no differences were observed in uri-
nalysis values between the groups. Finally, there were no 
reported adverse effects for use of the supplement or pla-
cebo. the blood chemistry and hematology, and urine data 
are presented in supplementary tables S4–S6.
Discussion
the primary findings of this study were that individu-
als consuming HMB-FA over 12 weeks of a periodized 
Table 3  Effect of beta-hydroxy-beta-methylbutyrate free acid (HMB-FA) supplementation on body composition and quadriceps depth in par-
ticipants performing a 12-week resistance-training regimen
Adjusted least square mean ± SD for n = 11 HMB-FA-supplemented (3 g HMB-FA/d in three 1 g doses) and n = 9 placebo-supplemented par-
ticipants
a
 Probability of treatment by time difference between the placebo and HMB-FA treatments over the 12-week study. the mixed model AnOVA 
in SAS was used with the main effects of treatment, time and treatment by time, with the value for week 0 used as a covariate of treatment
b
 DXA LBM Dual X-ray absorptiometry determined lean body mass
#
 Significantly different than corresponding placebo, t test (p < 0.05)
Week of study
0 4 8 12 p valuea
Weight (kg)
 Placebo 84.8 ± 0.9 85.7 ± 0.9 86.0 ± 0.9 85.1 ± 0.9
 HMB-FA 85.0 ± 0.9 85.8 ± 0.9 86.7 ± 0.9 86.9 ± 0.9# 0.003
DXA lBMb (kg)
 Placebo 67.1 ± 1.1 68.0 ± 1.1 70.0 ± 1.1 69.2 ± 1.1
 HMB-FA 67.1 ± 1.1 70.1 ± 1.1# 72.2 ± 1.1# 74.5 ± 1.1# 0.001
DXA fat (kg)
 Placebo 17.6 ± 1.7 16.8 ± 1.7 16.0 ± 1.7 15.9 ± 1.7
 HMB-FA 17.9 ± 1.7 15.7 ± 1.7 14.4 ± 1.7# 12.5 ± 1.7# 0.0003
Quadriceps depth (mm)
 Placebo 50.2 ± 2.1 52.2 ± 2.1 52.5 ± 2.1 52.6 ± 2.1
 HMB-FA 50.2 ± 2.1 53.1 ± 2.1 55.60 ± 2.1# 57.4 ± 2.1# 0.0001
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resistance-training program obtained greater gains in 
skeletal muscle hypertrophy, lBM, strength, and power 
in comparison to the placebo-supplemented group. the 
HMB-FA group also demonstrated increased loss of body 
fat compared with the placebo group. Finally, HMB-FA 
prevented declines in strength and power during the over-
reaching phase, and HMB-FA blunted the increase in mus-
cle damage and cortisol during this period of time.
Table 4  Effect of beta-hydroxy-beta-methylbutyrate free acid (HMB-FA) supplementation on serum creatine kinase (cK), cortisol, and per-
ceived recovery score (PrS) in participants performing a 12-week resistance-training regimen
Adjusted least square mean ± SD for n = 11 HMB-FA (3 g HMB-FA/d in three 1 g doses) and n = 9 placebo-supplemented participants
a
 Probability of treatment by time difference between the placebo and the HMB-FA treatments over the 12-week study. the mixed model in 
SAS was used with the main effects of treatment, week and treatment by week, with the value for week 0 used as a covariate
b
 Perceived recovery score is rated on the participants feeling of recovery from the last workout on a scale of 0–10
#
 Significantly different than corresponding placebo, t test (p < 0.05)
Week of study p valuea
0 4 8 12
creatine kinase (IU/l)
 Placebo 146 ± 62.3 388 ± 62.3 261 ± 62.3 195 ± 62.3
 HMB-FA 154 ± 62.3 275 ± 62.3# 251 ± 62.3 142 ± 62.3 0.01
cortisol (μg/dl)
 Placebo 20.3 ± 2.6 19.3 ± 2.6 19.9 ± 2.6 21.2 ± 2.6
 HMB-FA 21.0 ± 2.6 20.3 ± 2.6 18.2 ± 2.6 16.9 ± 2.6# 0.004
PrSb
 Placebo 9.1 ± 0.8 7.1 ± 0.8 7.7 ± 0.8 7.6 ± 0.8
 HMB-FA 9.1 ± 0.8 7.6 ± 0.8 8.5 ± 0.8# 9.5 ± 0.8# 0.003
Table 5  Effect of beta-hydroxy-beta-methylbutyrate free acid 
(HMB-FA) supplementation on serum creatine kinase (cK), urinary 
3-methylhistidine:creatinine ratio (3MH:cr), cortisol, and perceived 
recovery score (PrS) in participants during the overreaching phase, 
weeks 8, 9, and 10, of a 12-week resistance-training regimen
Adjusted least square mean ± SD for n = 11 HMB-FA (3 g HMB-FA free acid/d in three 1 g doses) and n = 9 placebo-supplemented partici-
pants
a
 Probability of treatment by time difference between the placebo and the HMB-FA treatments over weeks 8, 9, and 10, the overreaching por-
tion of the 12-week study. the mixed model in SAS was used with the main effects of treatment, week and treatment by week, with the value for 
week 8 as a covariate
b
 Perceived recovery score is rated on the participants feeling of recovery from the last workout on a scale of 0–10
#
 Significantly different than corresponding placebo, t test (p < 0.05)
Week of study p valuea
8 9 10
24 h 3MH:cr (μmol:mg)
 Placebo 0.124 ± 0.012 0.132 ± 0.012 0.152 ± 0.012
 HMB-FA 0.124 ± 0.012 0.120 ± 0.012 0.141 ± 0.012 0.34
creatine kinase (IU/l)
 Placebo 256 ± 119.8 494 ± 119.8 533 ± 119.8
 HMB-FA 256 ± 119.8 288 ± 119.8# 250 ± 119.8# 0.0001
cortisol (μg/dl)
 Placebo 19.1 ± 1.9 21.9 ± 1.9 23.5 ± 1.9
 HMB-FA 18.9 ± 1.9 19.8 ± 1.9# 18.8 ± 1.9# 0.003
PrSb
 Placebo 7.9 ± 0.8 5.0 ± 0.8 4.6 ± 0.8
 HMB-FA 8.4 ± 0.7 7.8 ± 0.7# 7.6 ± 0.7# 0.001
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the effects of HMB-FA on skeletal muscle hypertrophy 
and changes in lean body mass
Our results indicated greater increases in lBM and muscle 
thickness in the HMB-FA group as compared to the pla-
cebo group (table 3). these results agreed with Kraemer 
et al. (2009), who also reported large treatment effects fol-
lowing a 12-week-periodized program; however, this was 
in an untrained population. Previous research in trained 
populations has been inconsistent, with findings of both no 
effect (Kreider et al. 1999; Slater et al. 2001), or positive 
treatment effects on indices of muscle mass (nissen et al. 
1996; thomson et al. 2009). there are a number of pos-
sible reasons for the equivocal results observed across mul-
tiple study formats.
the literature suggests that in order to see an effect on 
skeletal muscle hypertrophy, the degree of undulation 
(e.g., periodization) and the duration of a training program 
should increase proportionally to the training status of the 
individual (Monteiro et al. 2009; turner 2011). Previous 
studies which used HMB in trained populations have lasted 
from 28 days (Kreider et al. 1999) to as long as 9 weeks 
in length (thomson et al. 2009). In general, when using 
HMB as an intervention in trained individuals, little to no 
changes in hypertrophy have been found in studies lasting 
<6 weeks in duration (Hoffman et al. 2004; Kreider et al. 
1999; Slater et al. 2001). It is conceivable that a duration 
of <6 weeks is not long enough to see significant changes 
in hypertrophy or lBM in experienced, resistance-trained 
individuals (Ahtiainen et al. 2003). Prior to our research, 
the longest duration study examining HMB supplementa-
tion in a trained population was conducted by thomson 
and colleagues (2009). this study contained unsupervised, 
non-periodized training sessions, had moderate (84 %) 
compliance, and utilized highly variable outcome meas-
ures of hypertrophy (bioelectrical impedance) (loenneke 
et al. 2012). However, despite these limitations, 9 weeks of 
HMB-ca supplementation resulted in small, but significant 
increases in fat free mass (thomson et al. 2009).
Our study in highly trained individuals utilized an intri-
cate design aimed at recapitulating skeletal muscle stress 
and damage often seen in individuals with low training 
experience (Kraemer et al. 2009). As such, our repeti-
tion scheme, intensity, and rest period lengths varied from 
workout to workout, from week to week, and from phase 1 
through phase 3 of the study (tables 1, 2, 3). Measures of 
cK confirmed that our design was novel enough to reca-
pitulate the skeletal muscle stress and damage often seen 
in individuals with low training experience. As such, par-
ticipants in the HMB-FA group experienced similar gains 
as has been previously observed in untrained populations. 
collectively, these findings suggest that HMB can aug-
ment increases in hypertrophy and lBM in both untrained 
and trained populations so long as the training stimulus 
is of great enough relative magnitude to cause significant 
and frequent perturbations to skeletal muscle. though the 
mechanisms of action involving HMB-FA have not fully 
been elucidated, it is currently thought to work through 
improving protein turnover and skeletal muscle regenera-
tion (Wilson et al. 2008; Zanchi et al. 2011). these expla-
nations were generally indicated in our study results by the 
overall lower skeletal muscle disruption throughout each 
measure of the 12 weeks of high-intensity training.
the effects of HMB-FA on skeletal muscle strength 
and power development
Strength and power are two of the most critical attrib-
utes underlying success in sport (robbins and Docherty 
2005; Wilson et al. 2012). these variables are intimately 
related and allow athletes to be successful in their respec-
tive sport (cormie et al. 2011a, b). the collective results 
of the present study, as well as those from Kraemer et al. 
(2009), suggest that changes in strength and power follow-
ing HMB supplementation are optimized within the context 
of a periodized as compared to a non-periodized training 
program (thomson et al. 2009). Moreover, it is conceiv-
able that the magnitude of strength and power adaptations 
resulting from HMB supplementation may be reflective 
of the measurement technique. For example, past research 
utilizing compound, sport-specific movements such as the 
squat, bench press, and vertical jump have found robust 
changes in strength and power following HMB supplemen-
tation (Kraemer et al. 2009; nissen et al. 1996). In contrast, 
researchers have found small treatment effects when using 
non-specific, isolated movements such as the leg extension 
and preacher curl (thomson et al. 2009). given that HMB 
augments skeletal muscle mass, it is likely that its benefits 
are more fully realized when expressed under multi-joint, 
compound movements (e.g., squat, deadlift), which stress a 
greater total amount of the skeletal muscle system.
the effects of HMB-FA on body fat
recent evidence from the laboratory of Michael Zemel at 
the University of tennessee (Bruckbauer et al. 2012) has 
demonstrated that HMB supplementation improves fatty 
acid oxidation, adenosine monophosphate kinase (AMPK), 
Sirt1, and Sirt3 activity in mouse-derived 3t3-l1 adipo-
cytes and c2c12 muscle cells. to elaborate, the Sirt pro-
teins (Silent information regulator transcripts) belong to a 
class of nAD+-dependent protein deacetylases involved in 
energy metabolism, which sense energy balance through 
changes in the nAD+/nADH ratio. Sirt proteins modify 
the acetylation level of histones and proteins (Verdin et al. 
2010). AMPK is also a sensor of energy balance, but does 
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so through changes in AMP/AtP ratios (Hardie 2003). col-
lectively, these proteins act to improve mitochondrial bio-
genesis, fat oxidation, energy metabolism, and the reactive 
oxygen defense system (Hardie 2003; Hardie et al. 2006; 
Verdin et al. 2010). consequently, this recent evidence has 
shown that HMB supplementation increases mitochondria 
biogenesis and fat oxidation (Stancliffe and Zemel 2012). 
While our primary aim was not to investigate HMB’s 
effects on fat mass, we did find that those supplementing 
with HMB-FA lowered body fat relative to the placebo 
group. these findings agreed with Kraemer et al. (2009), 
who also found that participants lost more body fat follow-
ing 12 weeks of HMB supplementation relative to a pla-
cebo-matched control.
the effects of HMB-FA on overreaching
the primary cause of overreaching appears to be an imbal-
ance between the training stimulus and recovery. Our 
results indicated that our overreaching cycle was able to 
decrease power, strength, and perceived recovery in the 
placebo, but not in the HMB-FA group. Moreover, HMB-
FA was able to blunt the characteristic rise in cK, an indi-
cator of skeletal muscle damage, and an elevation in the 
serum stress hormone cortisol following the overreaching 
cycle. Finally, following a 2-week taper in which the train-
ing volume was lowered, the placebo group regained their 
baseline performance, while the HMB-FA group expe-
rienced robust increases in both strength and power. the 
data provided in the present study exhibit strong evidence 
that HMB-FA interacts with the training stimulus itself. 
While our design was certainly innovative, the outcomes 
found agreed with the past literature. For example, HMB 
has been demonstrated to attenuate decreases in power 
and lBM in calorically restricted judo athletes subjected 
to high-intensity training loads (Hunga et al. 2010). HMB 
supplementation has also been found to acutely blunt rises 
in cortisol following resistance training (Kraemer et al. 
2009), as well as decrease or prevent the rise in serum 
indices of muscle damage (nissen et al. 1996; van Some-
ren et al. 2005), along with subjective measures of recov-
ery following rigorous acute training regimens (van Some-
ren et al. 2005).
Conclusions
the collective findings of our current study suggest that 
supplementation with HMB-FA in combination with a 
high-intensity, frequently undulating periodization training 
model results in increases in lBM, muscle hypertrophy, 
strength, and power. Moreover, when faced with greater 
training frequencies, as demonstrated with the overreaching 
cycle of training, HMB-FA may prevent typical declines 
in performance that are characteristic of overreaching. 
Future research should seek to elucidate the underlying 
mechanisms of HMB-FA in minimizing the negative and 
improving the positive effects of high-intensity training 
adaptations.
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